Jeff Thomis – Chairman
After a short career in academia, Dr Jeff Thomis spent 35 years in the clinical and commercial development of new medicines, the first 20 years at Bristol-Myers Squibb and then 15 years at Quintiles where he was President of Clinical Development Services and Chairman of the American Management Board. Since then he has held a number of Board positions including Non-Executive Chairman at Idis. He currently is Non-Executive Chairman of Quotient Sciences, sits on the board of Cesca Therapeutics , a market leader in cell based therapies, and NovaQuest, a US-based Health Care PE company. He is also a Senior Advisor to GHO Capital, a Health Care PE company.
Jaswinder Khera – Managing Director US
At WEP Clinical, Jaswinder oversees the growth and strategy of the business in the Americas. Jaswinder brings over 30 years of experience in the Pharmaceutical Industry in senior sales and marketing positions with Sanofi, MSD and Astra. He also held senior management positions in operations and business development during his 10 years with Quintiles.
Jaswant Khera – Managing Director EU
Following sales and management experience with Pfizer, where he led a team that marketed the global blockbusters Lipitor & Neurontin, Jaswant went on to launch WE Pharma, now called WEP Clinical. He brings with him 20 years of commercial, strategic, operational and marketing experience as well as a deep understanding of international markets and commercialization of drugs. Currently serving as Managing Director EU, he is responsible for the growth and strategy of the business.
Julian Phipps – Chief Financial Officer
Julian brings over 25 years’ experience of senior financial roles in various Groups including Capita, SunGard and Northgate. Julian was the Group auditor of Ciba-Geigy in the five years leading up to the merger with Sandoz that created Novartis. Julian also brings significant experience of mergers and acquisitions to the WEP Clinical team.
Matt Comstock – Vice President, Business Development
Matt has nearly two decades of experience working in the Pharmaceutical and CRO space. He worked previously in data management and finance at Quintiles for nearly 15 years, and also has experience in research, strategic account management, sales and relationship development. As the Business Development Director at WEP Clinical, Matt is responsible for developing new customer accounts as well as growing relationships with existing customers.
Lee Holmes – Head of Commercial
Lee brings broad industry knowledge and expertise to WEP having worked in the healthcare industry for over 20 years. His experience ranges from commercial leadership, alliance and distributor management to business development & licensing and R&D. Prior to joining WEP, he spent several years at Clinigen, and spent a decade at BTG in a multitude of different roles. At WEP, he is responsible for the commercial direction of the company, taking us through our next, exciting phase of growth and development.
Brian Hood – Head Of Operations
With over 25 years’ experience in managing complex and regulated global supply chains Brian heads up our logistical and quality operations in the EU. Previous experiences include 3PL management, project management, client and vendor relationship management and lean process improvement systems. Prior to joining WEP Brian spent several years at Idis and Clinigen managing global distribution and secondary packaging production networks in the UK, EU, Asia and North America.
Amandip Sidhu – Expanded Access Programs Director
Amandip has harnessed a clinical background in pharmacy to develop industry-leading solutions. Previously, as part of an international PLC healthcare company, he was responsible for creating and implementing the company’s EAP strategy. Now at WEP Clinical, Amandip is responsible for overseeing all expanded access activities and ensuring WEP’s programs are run efficiently and to the highest standard of quality.
Carlos Marafusta – Business Development Director
Carlos joined WEP Clinical in 2013 and is currently the Business Development Director in the EU. He has an in-depth knowledge of the unlicensed specialty care market and over 20 years experience in the industry across a range of disciplines, including commercial, strategic, operational and sales and marketing roles for companies such as Bristol Myers Squibb and Astra Zeneca.
Megan Batchelor – Operations & Quality Director
Megan has been in the pharmaceutical industry for over eight years and has extensive experience in facility startup, quality operations, engineering, and project management. She joined WEP Clinical in 2016, after working at Novartis Vaccines & Diagnostics, and currently serves as the company’s Operations & Quality Director. In her role, Megan is responsible for helping to grow and develop quality systems and processes while focusing on continuous improvement of current operational processes.
Entrane Harvey – Director of Project Management
Entrane has been in the Pharmaceutical and CRO industry for over twenty-seven years with extensive experience in Clinical Operations and Global Project Management. He joined WEP Clinical in 2017 after working at Glaxo SmithKline. In his current role, Entrane is responsible for the growth of Expanded Access Clinical and Project Management Operations. His approach to solid project management systems and processes drives value and superior quality for our clients.
Sean Quigley – Operations Manager
Sean Quigley manages the warehouse and logistical operations of WEP EU and brings with him 25 years of experience in supply chain management. Having previously worked for AAH he has managed end-to-end logistics operations, covering the full range of medicines including Controlled Drugs and Temperature sensitive product, as well as overseeing stock management. He supports the sales teams to develop bespoke logistics solutions for WEP’s customers.
Richard Crawley – Regulatory Affairs
Richard has over forty years’ experience in the pharmaceutical industry in preclinical drug metabolism and pharmacokinetics, global regulatory affairs and drug development planning and management. He has served in senior regulatory positions with the Welcome Foundation (UK), Burroughs Welcome (USA) and Pozen Inc. (USA), covering Phase I – IV development activities, and he has extensive experience interacting with worldwide regulatory authorities.
Chris Barnett – Regulatory Affairs
Experience in the principles of International Quality Assurance and project and line management gained in various tenures at the Wellcome Foundation Limited, Glaxo Wellcome and Glaxo SmithKline, led Chris to his certification as an EU Qualified Person (QP) with particular expertise in clinical trial materials. His forty years of experience enables him to provide expert knowledge of the principles and regulation of Good Manufacturing Practice (GMP), Good Distribution Practice (GDP) and Quality Assurance.